Эффективность воздействия новейшего антидепрессанта агомелатина на расстройства циркадианного цикла отдых-активность, депрессивные и тревожные симптомы у пациентов с большим депрессивным расстройством: рандомизированное



Скачать 384.89 Kb.
страница3/3
Дата24.04.2016
Размер384.89 Kb.
1   2   3

Д-р Kasper получал грант/исследовательскую поддержку от компаний Eli Lilly, Lundbeck, Bristol-Myers Squibb, GlaxoSmithKline, Organon, Sepracor и Servier; выполнял обязанности консультанта или участвовал в экспертных советах для компаний AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Eli Lilly, Lundbeck, Pfizer, Organon, Schwabe, Sepracor, Servier, Janssen и Novartis; и выступал в качестве докладчика для компаний AstraZeneca, Eli Lilly, Lundbeck, Schwabe, Sepracor, Servier, Pierre Fabre и Janssen. Д-р Hajak выступал в качестве докладчика для компаний AstraZeneca, Bayer Vital, Bristol-Myers Squibb, Boehringer Ingelheim, Cephalon, EuMeCom, GlaxoSmithKline, Janssen-Cilag, Eli Lilly, Lundbeck, Merz, Neurim, Novartis, Organon, Pfizer, Sanofi-Aventis, Servier, Takeda и Wyeth; выполнял обязанности консультанта или участвовал в экспертных советах для компаний Actelion, AstraZeneca, Bristol-Myers Squibb, Euro RSCG Life Worldwide, Gerson Lerman Group, Janssen-Cilag, Eli Lilly, Lundbeck, McKinsey, Merck, Network Advisors, Neurim, Neurocrine, Novartis, Organon, Pfizer, Proctor & Gamble, Purdue, Sanofi-Aventis, Schering Plough, Sepracor, Servier, Takeda и Wyeth; получал спонсорскую помощь для исследований от компаний Actelion, AstraZeneca, Boehringer Ingelheim, BrainLab, GlaxoSmithKline, Lundbeck, Neurim, Novartis, Organon, Orphan, Sanofi-Aventis, Sepracor, Servier и Takeda. Д-р Wulff получал гонорары за анализ данных и консультации от компании Servier. Д-р Hoogendijk выступал с лекциями и участвовал в экспертных советах для компаний Lundbeck, Servier, Eli Lilly и Organon/Schering Plough, для которых Founda­tion for Depression Research GGZBA получали гранты и заработную плату. Д-р Montejo получал гонорары от компаний Servier, Eli Lilly, Bristol-Myers Squibb, GlaxoSmithKline, Sanofi, AstraZeneca, Boehringer и Wyeth и участвовал в экспертных советах для компаний Eli Lilly, Boehringer, GlaxoSmithKline, Servier и AstraZeneca. Д-р Smeraldi выполнял обязанности консультанта или докладчика для компаний Janssen-Cilag, Innova-Pharma и Wyeth. Д-р Rybakowski выполнял обязанности консультанта или докладчика для компаний Adamed-Poland, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Janssen-Cilag, Lundbeck, Organon, Pfizer, Sanofi-Aventis и Servier. Д-р Quera-Salva выполнял обязанности консультанта или участника экспертного совета для компании Servier. Д-р Wirz-Justice выполняла обязанности консультанта и докладчика для компании Servier. Д-р Picarel-Blanchot является сотрудником компании Servier. Д-р Bayle получал гонорары от компаний Bristol-Myers Squibb, Janssen-Cilag, Servier, Sanofi-Aventis, UCB Pharma Исследовательскую поддержку Bioprojet, Eli Lilly, Janssen-Cilag и Servier.

Финансирование/поддержка: Данное исследование спонсировалось компанией Servier (Courbevoie, France).

Предыдущие презентации результатов: Результаты исследования были представлены на 26-м конгрессе Международного колледжа по нейропсихофармакологии (Collegium Internationale Neuro-Psychopharmalogicum), 13-17 июля 2008, Мюнхен, Германия и 21-м конгрессе Европейского колледжа по нейропсихофармакологии (European College Neuropsychopharmacology), 30 августа – 3 сентября 2008 г., Барселона, Испания.

Выражение благодарности: Работа доктора Wulff была поддержана NIHR Biomedical Research Centre, Оксфорд, Великобритания.
СПИСОК ЛИТЕРАТУРЫ

  1. Volkers AC, Tulen JH, van den Broek WW, et al. Motor activity and auto­nomic cardiac functioning in major depressive disorder. J Affect Disord. 2003;76(1-3):23-30.

  2. Germain A, Kupfer DJ. Circadian rhythm disturbances in depression. Hum Psychopharmacol. 2008;23(7):571-585.

  3. Wirz-Justice A, Campbell IC. Antidepressant drugs can slow or dissociate circadian rhythms. Experientia. 1982;38(11):1301-1309.

  4. Benca RM, Peterson MJ. Insomnia and depression. Sleep Med. 2008; 9(suppl 1):S3-S9.

  5. Birchler-Pedross A, Schroder CM, Munch M, et al. Subjective well-being is modulated by circadian phase, sleep pressure, age and gender. J Biol Rhythms. 2009;24(3):232-242.

  6. Boivin DB, Czeisler CA, Dijk DJ, et al. Complex interaction of the sleep-wake cycle and circadian phase modulates mood in healthy subjects. Arch Gen Psychiatry. 1997;54(2):145-152.

  7. Zhou JN, Riemersma RF, Unmehopa UA, et al. Alterations in arginine vasopressin neurons in the suprachiasmatic nucleus in depression. Arch Gen Psychiatry. 2001;58(7):655-662.

  8. Thase ME. Antidepressant treatment of the depressed patient with in­somnia. J Clin Psychiatry. 1999;60(suppl 17):28-31, discussion 46-48.

  9. Judd LL, Akiskal HS, Maser JD, et al. Major depressive disorder: a pro­spective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Disord. 1998;50(2-3):97-108.

  10. Cho HJ, Lavretsky H, Olmstead R, et al. Sleep disturbance and depres­sion recurrence in community-dwelling older adults: a prospective study. Am J Psychiatry. 2008;165(12):1543-1550.

  11. Wilson S, Argyropoulos S. Antidepressants and sleep: a qualitative review of the literature. Drugs. 2005;65(7):927-947.i IH^I

  12. Mayers AG, Baldwin DS. Antidepressants and their effect on sleep. Hum Psychopharmacol. 2005;20(8):533-559.

  13. Bauer M, Bschor T, Pfennig A, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care. World J Biol Psychiatry. 2007;8(2):67-104.

  14. Rascati K. Drug utilization review of concomitant use of specific sero­tonin reuptake inhibitors or clomipramine with antianxiety/sleep medications. Clin Ther. 1995;17(4):786-790.

  15. Jean-Louis G, Mendlowicz MV, Gillin JC, et al. Sleep estimation from wrist activity in patients with major depression. Physiol Behav. 2000;70(1-2):49-53.

  16. Raoux N, Benoit O, Dantchev N, et al. Circadian pattern of motor ac­tivity in major depressed patients undergoing antidepressant therapy: relationship between actigraphic measures and clinical course. Psychiatry Res. 1994;52(1):85-98.

  17. Winkler D, Pjrek E, Praschak-Rieder N, et al. Actigraphy in patients with seasonal affective disorder and healthy control subjects treated with light therapy. Biol Psychiatry. 2005;58(4):331-336.

  18. Millan MJ, Gobert A, Lejeune F, et al. The novel melatonin agonist ago-melatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther. 2003;306(3):954-964.

  19. Yous S, Andrieux J, Howell HE, et al. Novel naphthalenic ligands with high affinity for the melatonin receptor. J Med Chem. 1992;35(8): 1484-1486.

  20. Papp M, Gruca P, Boyer PA, et al. Effect of agomelatine in the chronic mild stress model of depression in the rat. Neuropsychopharmacology. 2003;28(4):694-703.

  21. Kasper S, Hamon M. Beyond the monoaminergic hypothesis: agomela-tine, a new antidepressant with an innovative mechanism of action. World J Biol Psychiatry. 2009;10(2):117-126.

  22. Fuchs E, Schmelting B, Mocaer E. Effects of the novel antidepressant ago-melatine (S 20098) and f1uoxetine in chronically stressed tree shrews, an animal model of depression. Eur Neuropsychopharmacol. 2006;16:S338.

  23. Krauchi K, Cajochen C, Mori D, et al. Early evening melatonin and S-20098 advance circadian phase and nocturnal regulation of core body temperature. Am J Physiol. 1997;272(4, Pt 2):R1178-R1188.

  24. Kennedy SH, Emsley R. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur Neuropsychopharmacol. 2006;16(2):93-100.

  25. Loo H, Hale A, D'haenen H. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol. 2002;17(5):239-247.

  26. Olie JP, Kasper S. Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. Int J Neuropsychopharmacol. 2007;10(5):661-673.

  27. Lemoine P, Guilleminault C, Alvarez E. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomela-tine: randomized, double-blind comparison with venlafaxine. J Clin Psychiatry. 2007;68(11):1723-1732.

  28. Kennedy SH, Rizvi S, Fulton K, et al. A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR. J Clin Psychopharmacol. 2008;28(3): 329-333.

  29. Quera Salva MA, Vanier B, Laredo J, et al. Major depressive disorder, sleep EEG and agomelatine: an open-label study. Int J Neuropsychopharmacol. 2007;10(5):691-696.

  30. Hindmarch I, Bhatti JZ. Psychopharmacological effects of sertraline in normal, healthy volunteers. Eur J Clin Pharmacol. 1988;35(2):221-223.

  31. Jindal RD, Friedman ES, Berman SR, et al. Effects of sertraline on sleep architecture in patients with depression. J Clin Psychopharmacol. 2003;23(6):540-548.

  32. Ancoli-Israel S, Cole R, Alessi C, et al. The role of actigraphy in the study of sleep and circadian rhythms. Sleep. 2003;26(3):342-392.

  33. Preskorn SH, Lane RM. Sertraline 50 mg daily: the optimal dose in the treatment of depression. Int Clin Psychopharmacol. 1995;10(3):129-141.

  34. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000.

  35. Sheehan DV, Lecrubier Y, Harnett Sheehan K, et al. The validity of the Mini International Neuropsychiatric Interview (MINI) according to the SCID-P and its reliability. Eur Psychiatry. 1997;12(5):232-241.

  36. Dodd A, Hare DJ, Arshad P. The use of melatonin to treat sleep disorder in adults with intellectual disabilities in community settings—the evalua­tion of three cases using actigraphy. J Intellect Disabil Res. 2008;52(Pt 6):547-553.

  37. Lahti TA, Haukka J, Lonnqvist J, et al. Daylight saving time transitions and hospital treatments due to accidents or manic episodes. BMC Public Health. 2008;8(1):74.

  38. Parrott AC, Hindmarch I. Factor analysis of a sleep evaluation question­naire. Psychol Med. 1978;8(2):325-329.

  39. Zisapel N, Nir T. Determination of the minimal clinically significant difference on a patient visual analog sleep quality scale. J Sleep Res. 2003;12(4):291-298.

  40. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56-62.

  41. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32(1):50-55.

  42. Guy W. ECDEU Assessment Manual for Psychopharmacology.US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, MD: National Institute of Mental Health; 1976:218-222.

  43. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika. 1988;75(4):800-802.

  44. Acebo C, LeBourgeois MK. Actigraphy. Respir Care Clin North Am. 2006;12(1):23-30, viii.

  45. Korszun A, Young EA, Engleberg NC, et al. Use of actigraphy for monitoring sleep and activity levels in patients with fibromyalgia and depression. J Psychosom Res. 2002;52(6):439-443.

  46. Rowe M, McCrae C, Campbell J, et al. Actigraphy in older adults: comparison of means and variability of three different aggregates of measurement. Behav Sleep Med. 2008;6(2):127-145.

  47. Sadeh A, Hauri PJ, Kripke DF, et al. The role of actigraphy in the evaluation of sleep disorders. Sleep. 1995;18(4):288-302.

  48. Saletu B, Grunberger J. Drug profiling by computed electroencephalo-graphy and brain maps, with special consideration of sertraline and its psychometric effects. J Clin Psychiatry. 1988;49(suppl):59-71.

  49. Goodwin GM, Emsley R, Rembry S. Agomelatine prevents relapse in patients with major depressive disorder, without evidence of a disconti uation syndrome. J Clin Psychiatry. 2009;70:1128-1137.

  50. Kennedy SH, Guilleminault C. Antidepressant efficacy of agomelatine 25-50 mg versus venlafaxine 75-150 mg: two randomized, double-blind studies. Eur Neuropsychopharmacol. 2006;16:S319.

  51. Hale A, Corral R, Mencacci R, et al. Superior antidepressant efficacy of agomelatine vs fluoxetine in severe major depressive disorder pa­tients: a randomised, double-blind study. Eur Neuropsychopharmacol. 2009;19:S418-S419.

  52. Cipriani A, Furukawa TA, Geddes JR, et al. MANGA Study Group. Do randomized evidence support sertraline as first-line antidepressant for adults with acute major depression? a systematic review and meta-analysis. J Clin Psychiatry. 2008;69(11):1732-1742.

  53. Santen G, Gomeni R, Danhof M, et al. Sensitivity of the individual item of the Hamilton depression rating scale to response and its consequenc for the assessment of efficacy. J Psychiatr Res. 2008;42(12):1000-1009.

  54. Bech P, Gram LF, Dein E, et al. Quantitative rating of depressive states. Acta Psychiatr Scand. 1975;51(3):161-170.

  55. Melander H, Salmonson T, Abadie E, et al. A regulatory apologia— a review of placebo-controlled studies in regulatory submissions of new-generation antidepressants. Eur Neuropsychopharmacol. 2008;18(9):623-627.

  56. Zisapel N, Laudon M. Subjective assessment of the effects of CNS-activ drugs on sleep by the Leeds Sleep Evaluation Questionnaire: a review. Hum Psychopharmacol. 2003;18(1):1-20.

  57. Montejo A, Prieto N, Terleira A, et al. Better sexual acceptability of agomelatine (25 and 50 mg) compared with paroxetine (20 mg) in healthy male volunteers: an 8-week, placebo-controlled study using the PRSEXDQ-SALSEX scale [published online ahead of print November 21, 2008]. J Psychopharmacol.





1   2   3


База данных защищена авторским правом ©bezogr.ru 2016
обратиться к администрации

    Главная страница